BofA raised the firm’s price target on Gilead (GILD) to $126 from $116 and keeps a Buy rating on the shares. For the last several weeks, ...

Q4 2024 Earnings Call Transcript March 4, 2025 Compugen Ltd. misses on earnings expectations. Reported EPS is $-0.07 EPS, ...

In a report released today, Tim Anderson from Bank of America Securities maintained a Buy rating on Gilead Sciences (GILD – Research Report), ...

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $140.00.

Gilead Sciences (NASDAQ:GILD – Free Report) had its price target raised by Oppenheimer from $115.00 to $132.00 in a report ...

Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibody On track to initiate a randomized adaptive ...

Oppenheimer raised the firm’s price target on Gilead (GILD) to $132 from $115 and keeps an Outperform rating on the shares. The firm says that ...

In the latest market close, Gilead Sciences (GILD) reached $115.99, with a +1.47% movement compared to the previous day. This move outpaced the S&P 500's daily loss of 1.76%. Meanwhile, the Dow ...

Stock analysts at Zacks Research reduced their Q3 2026 earnings per share estimates for shares of Gilead Sciences in a research report issued on Tuesday, February 25th. Zacks Research analyst E. Bagri ...